Abstract OT2-30-01: Nordictrip, a translational randomized phase-3study exploring the effect of the addition of capecitabine to carboplatinum-based chemotherapy in early “triple negative” breast cancer, ClinicalTrials.gov Identifier: NCT04335669
Niklas Loman(Lund University), Henrik Lindman(Uppsala University), Anders Ståhlberg(Lund University), Minna Tanner(Tampere University Hospital), Åke Borg(Lund University), Eva-Christin Kjellman(Skåne University Hospital), Bent Ejlertsen, Ann Julia Raaberg(Rigshospitalet), Johan Ahlgren(Uppsala University), Lina Zander(Skåne University Hospital), Johan Staaf(Lund University), Olöf Bjarnadóttir(National University Hospital of Iceland), Barbro Linderholm(Karolinska University Hospital), Pär‐Ola Bendahl(Lund University), Anne‐Vibeke Lænkholm, Heidi Grill Magnusson(Skåne University Hospital), Óskar Þór Jóhannsson(National University Hospital of Iceland), Maj-Britt Raaby Jensen(Rigshospitalet), Siker Kimbung(Lund University)
Cited by 0
Related Papers
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
|The Lancet|2010|1.6k
The Life History of 21 Breast Cancers
|Cell|2012|1.5k